# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Franklin D. Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET002-SYN
- Date: 2026-09-25
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathaniel Brooks, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month heart failure review with repeat echocardiogram. **S**

## History of present illness

Mr. Roosevelt returns for his six-month review and repeat echocardiogram. The stomach illness in July settled within four days; he restarted his heart failure medicines on the third day without lightheadedness, and his weight is back to 82 kg. He is finishing an adapted cardiac rehabilitation program of seated arm-cycle and resistance-band training and will keep up the band exercises at home three times a week. He propels his wheelchair on level ground and up short ramps without breathlessness, sleeps on one pillow, and has had no leg swelling since furosemide stopped. His home blood pressures run 115 to 125 systolic, and he has had no lightheadedness on transfers. He has not smoked since April. He prefers not to raise his medicine doses further for now, because safe transfers matter more to him than small further gains, and the July illness showed how quickly his blood pressure can fall. **S**

| Element | Detail |
|---|---|
| Interval change | July gastroenteritis resolved in four days; medicines restarted on the third day |
| Function | Level ground and short ramps without breathlessness; finishing cardiac rehabilitation |
| Weight log | Back to 82 kg; no swelling off furosemide |
| Home blood pressure | 115 to 125 systolic |
| Tobacco | No cigarettes since April |
| Patient preference | No further dose increases for now, to protect safe transfers |
| NYHA class | I to II |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Good energy; weight stable |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or leg swelling |
| Respiratory | Negative | No breathlessness on level ground or short ramps |
| Gastrointestinal | Negative | Bowel habit back to his usual since July |
| Neurological | Negative | No lightheadedness on transfers |
| Musculoskeletal | Negative | No muscle aches; no shoulder pain with rehabilitation exercise |

6 systems reviewed. **S**

## Current medications

- Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice daily **S**
- Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with food **S**
- Spironolactone 25 mg oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 64 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 82 kg; BMI 23.2 kg/m². All vital signs are synthetic.

NT-proBNP: 410 pg/mL (high); Sodium: 139 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 1.21 mg/dL; eGFR: 68 mL/min/1.73 m²; Glucose: 95 mg/dL; LDL cholesterol: 68 mg/dL; Urine albumin-creatinine ratio: 22 mg/g; LVEF by echocardiogram: 45% (low); KCCQ-12 overall summary: 78. All results are synthetic.

## Change since baseline

- NT-proBNP: 2850 pg/mL (high) at baseline, 410 pg/mL (high) at this visit **S**
- Sodium: 137 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 1.18 mg/dL at baseline, 1.21 mg/dL at this visit **S**
- eGFR: 70 mL/min/1.73 m² at baseline, 68 mL/min/1.73 m² at this visit **S**
- Glucose: 104 mg/dL (high) at baseline, 95 mg/dL at this visit **S**
- LDL cholesterol: 132 mg/dL (high) at baseline, 68 mg/dL at this visit **S**
- Urine albumin-creatinine ratio: 64 mg/g (high) at baseline, 22 mg/g at this visit **S**
- KCCQ-12 overall summary: 38 at baseline, 78 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 82 kg on the wheelchair scale |
| Neck | Jugular venous pressure 6 cm |
| Lungs | Clear |
| Heart | Regular rhythm, rate 64; no S3 |
| Extremities | No edema; dorsalis pedis and posterior tibial pulses palpable in both feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with improved ejection fraction** (I50.22). Ejection fraction 45 percent today, up from 30 percent in April: heart failure with improved ejection fraction (a rise of at least 10 points to above 40 percent). NYHA class I to II, KCCQ-12 78 (up 40 points), and NT-proBNP 410 pg/mL, down from 2850. Potassium 4.5 mmol/L and creatinine 1.21 mg/dL (eGFR 68), back to baseline after the July illness. Sacubitril/valsartan 49/51 mg and carvedilol 12.5 mg twice daily are below target doses; at his request, and given his dependence on safe independent transfers, these are accepted as his tolerated doses for now. **S**
   - Continue sacubitril/valsartan, carvedilol, spironolactone, and empagliflozin; therapy continues even though the ejection fraction has improved.
   - No implantable defibrillator: the ejection fraction is above 35 percent.
   - Revisit dose increases at the three-month review.
   - Basic metabolic panel with magnesium, KCCQ-12, and ECG at the three-month review.
2. **Hypertensive heart disease** (I11.0). Blood pressure 122/76 mmHg, below the 130/80 target, meeting his goal. Urine albumin-creatinine ratio 22 mg/g, down from 64 and now normal. **S**
   - No change.
   - Eye examination for hypertensive retinopathy, to be arranged at next month's preventive visit.
3. **Hyperlipidemia** (E78.5). LDL cholesterol 68 mg/dL, down 48 percent from 132 on atorvastatin 40 mg, below the 70 mg/dL target. **S**
   - Continue atorvastatin 40 mg.
   - Lipid panel yearly; lipoprotein(a) once, with the next laboratory tests.
4. **Nicotine dependence, cigarettes, in early remission** (F17.210). No cigarettes since April. **S**
   - Relapse-prevention advice.
   - Lung cancer screening eligibility to be discussed at next month's preventive visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | Every 3 to 6 months when stable | Completed today | Potassium 4.5, creatinine 1.21 mg/dL, eGFR 68; back to baseline after creatinine 1.42 at the July sick visit |
| Laboratory | Basic metabolic panel after stopping furosemide in June | 1 to 2 weeks after a diuretic change | Deferred | Not drawn in the window, a deviation from the protocol. The next panel was at the July sick visit, about four and a half weeks later, with potassium 4.9 during volume depletion; today's potassium is 4.5, so no harm resulted. This is the second missed post-change check this year; the corrective action is the dated laboratory appointment at every medication change |
| Laboratory | Basic metabolic panel after restarting the medicines held in July | 1 to 2 weeks after restarting sacubitril/valsartan, spironolactone, and empagliflozin | Deferred | The sick-visit plan moved the recheck to today; strictly, the protocol calls for a panel within two weeks of a restart, so this is recorded as a deviation. Today's potassium and creatinine are at baseline, so no harm resulted. Corrective action: a panel one to two weeks after any future sick-day restart |
| Laboratory | Magnesium | With each basic metabolic panel | Deferred | Not measured with any panel since diagnosis, a deviation from the protocol. He has had no arrhythmia or cramps and has been off the loop diuretic since June, so the risk of low magnesium is small. Corrective action: added to the three-month panel |
| Laboratory | NT-proBNP | Selectively in outpatient follow-up | Completed today | 410 pg/mL, down from 2850; supports prognosis and decongestion |
| Imaging | Transthoracic echocardiogram | 3 to 6 months after therapy is optimized | Completed today | Ejection fraction 45 percent, up from 30: heart failure with improved ejection fraction. No device therapy is indicated, and routine repeat imaging is not recommended |
| Imaging | 12-lead ECG | At initial evaluation; repeat with device consideration | Deferred | Still not on file, a deviation carried from April. No device decision is needed now that the ejection fraction is 45 percent, and his rhythm is regular, so no harm has resulted. Corrective action: ECG at the three-month review |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit; every 3 to 6 months when stable | Completed today | Euvolemic at 82 kg |
| Survey | NYHA functional class | Every visit | Completed today | Class I to II |
| Survey | KCCQ-12 | Every 3 to 6 months | Completed today | 78, up 40 points from baseline |
| Survey | Depression screen (PHQ-2) | Periodically | Due | Score 0 in June; repeat at next month's preventive visit |
| Referral | Cardiac rehabilitation | Periodic review of participation and exercise capacity | Up to date | Finishing the adapted program; home resistance-band exercise three times a week to follow |
| Medication safety | Dose review of guideline-directed therapy | Each visit while titrating | Completed today | Sacubitril/valsartan and carvedilol remain below target doses by shared decision, to protect transfer safety; revisit at the three-month review |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin; then yearly | Completed today | LDL cholesterol 68 mg/dL, a 48 percent fall, below 70 mg/dL. Drawn 26 weeks after the start, outside the window (deviation recorded in June); the response is adequate, so no harm resulted |
| Laboratory | Lipoprotein(a) | Once in adulthood | Due | Not yet measured; add to the next laboratory tests |
| Laboratory | Urine albumin-creatinine ratio | Yearly in hypertension | Completed today | 22 mg/g, down from 64; now normal |
| Laboratory | HbA1c for prediabetes | Yearly | Up to date | 5.9 percent at diagnosis; glucose 95 mg/dL today |
| Laboratory | Hemoglobin and iron studies | Yearly in heart failure with reduced or improved ejection fraction | Up to date | Repleted in June |
| Examination | Funduscopic examination | Yearly in chronic hypertension | Due | Last eye examination more than two years ago; to be arranged at next month's preventive visit |
| Examination | Peripheral pulses and ankle-brachial index | Every 2 to 3 years with a smoking history | Due | Foot pulses palpable today; ankle-brachial index not yet done and due within the interval |
| Survey | 10-year ASCVD risk estimate | Yearly in hypertension | Not indicated | Not calculated: he already takes a statin for his LDL cholesterol and hypertensive heart disease, so the estimate would not change treatment |
| Medication safety | Tobacco use | Every visit | Completed today | Abstinent since April |
| Medication safety | Influenza vaccine | Every season | Due | Planned at next month's preventive visit |
| Self-management | Home blood pressure and daily weight log; low-sodium diet | Every visit | Completed today | Log reviewed; weights stable without furosemide |

## Goal progress

- Lower blood pressure below 130/80 by the six-month review. Outcome by 2026-09-25: Blood pressure 122/76. **S**
- Improve the KCCQ-12 overall summary score by at least 20 points by the three-month review. Outcome by 2026-06-26: KCCQ-12 rose from 38 to 64. **S**
- Stop smoking by the three-month review. Outcome by 2026-06-26: No cigarettes since April; nicotine patch course completed. **S**
- Reach the highest tolerated doses of guideline-directed therapy by the six-month review. Outcome by 2026-09-25: Sacubitril/valsartan 49/51 mg twice daily, carvedilol 12.5 mg twice daily, spironolactone, and empagliflozin. **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026), Aether Forge
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force

## Follow-up

- Preventive visit next month. Heart failure review in three months with a basic metabolic panel with magnesium, an ECG, the KCCQ-12, and a decision on dose increases. **S**
- Next scheduled visit 2026-10-23: periodic adult preventive visit. **S**
